

Yutaka Yasui

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5323483/publications.pdf>

Version: 2024-02-01

82
papers

2,319
citations

185998

28
h-index

233125

45
g-index

83
all docs

83
docs citations

83
times ranked

2940
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. <i>Hepatology</i> , 2010, 52, 518-527.	3.6	265
2	Î±-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. <i>Hepatology</i> , 2013, 58, 1253-1262.	3.6	227
3	Early Decrease in Î±-Fetoprotein, but Not Des-Î³-Carboxy Prothrombin, Predicts Sorafenib Efficacy in Patients with Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2011, 81, 251-258.	0.9	78
4	Expression of Keratin 19 Is Related to High Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation. <i>Oncology</i> , 2011, 80, 278-288.	0.9	67
5	Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy. <i>Hepatology Research</i> , 2010, 40, 870-877.	1.8	65
6	A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. <i>Hepatology Research</i> , 2010, 40, 251-260.	1.8	58
7	Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. <i>Cancer</i> , 2014, 120, 229-237.	2.0	57
8	<i>Wisteria floribunda</i> agglutinin positive human Mac-2 binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. <i>Hepatology Research</i> , 2015, 45, E82-8.	1.8	55
9	Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. <i>Hepatology</i> , 2012, 55, 20-29.	3.6	54
10	L-carnitine Reduces Muscle Cramps in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1540-1543.	2.4	53
11	Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma. <i>PLoS ONE</i> , 2018, 13, e0198812.	1.1	51
12	Up to seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization. <i>Hepatology Research</i> , 2018, 48, 442-450.	1.8	49
13	Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2004-2010.	1.4	48
14	Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients. <i>Journal of Gastroenterology</i> , 2014, 49, 1495-1503.	2.3	44
15	Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy. <i>World Journal of Gastroenterology</i> , 2013, 19, 249.	1.4	44
16	Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. <i>PLoS ONE</i> , 2020, 15, e0231828.	1.1	42
17	<i>Wisteria floribunda</i> agglutinin positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus. <i>Hepatology Research</i> , 2018, 48, 1131-1139.	1.8	40
18	Potential Relevance of Cytoplasmic Viral Sensors and Related Regulators Involving Innate Immunity in Antiviral Response. <i>Gastroenterology</i> , 2008, 134, 1396-1405.	0.6	39

#	ARTICLE	IF	CITATIONS
19	Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 292-301.	1.9	38
20	Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy. <i>Hepatology Research</i> , 2015, 45, E115-21.	1.8	37
21	Urinary excretion of the water channel aquaporin-2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites. <i>Journal of Gastroenterology</i> , 2016, 51, 620-627.	2.3	36
22	Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2960-2966.	1.4	36
23	Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice. <i>Investigational New Drugs</i> , 2022, 40, 392-402.	1.2	36
24	Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin. <i>Antiviral Therapy</i> , 2011, 16, 685-694.	0.6	35
25	Rethinking Success in Pediatric Oncology: Beyond 5-Year Survival. <i>Journal of Clinical Oncology</i> , 2021, 39, 2227-2231.	0.8	34
26	Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0154558.	1.1	34
27	Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. <i>Liver Transplantation</i> , 2014, 20, 291-297.	1.3	33
28	Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma: Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice. <i>Cancers</i> , 2019, 11, 1517.	1.7	30
29	Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2014, 49, 1152-1162.	2.3	28
30	Non-alcoholic fatty liver disease fibrosis score and FIB-4 scoring system could identify patients at risk of systemic complications. <i>Hepatology Research</i> , 2015, 45, 667-675.	1.8	26
31	Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2019, 26, 893-899.	1.0	25
32	<i>Wisteria floribunda</i> agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease. <i>Scientific Reports</i> , 2019, 9, 10109.	1.6	24
33	Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio. <i>PLoS ONE</i> , 2017, 12, e0174649.	1.1	24
34	Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures. <i>PLoS ONE</i> , 2019, 14, e0211122.	1.1	23
35	Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients. <i>Hepatology Research</i> , 2014, 44, 720-727.	1.8	22
36	Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens. <i>PLoS ONE</i> , 2015, 10, e0137351.	1.1	22

#	ARTICLE	IF	CITATIONS
37	Noninvasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infection. <i>Hepatology Research</i> , 2019, 49, 33-41.	1.8	22
38	Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis. <i>Hepatology Research</i> , 2020, 50, 1375-1385.	1.8	22
39	Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1171-1173.e2.	2.4	22
40	Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e3349-e3354.	2.9	21
41	Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib. <i>Hepatology Research</i> , 2020, 50, 137-143.	1.8	19
42	Reduced Organic Anion Transporter Expression Is a Risk Factor for Hepatocellular Carcinoma in Chronic Hepatitis C Patients: A Propensity Score Matching Study. <i>Oncology</i> , 2014, 86, 53-62.	0.9	18
43	Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy. <i>PLoS ONE</i> , 2015, 10, e0138060.	1.1	18
44	Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1595-1601.	1.4	18
45	Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. <i>Cancer Medicine</i> , 2016, 5, 3111-3120.	1.3	17
46	Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1256.	1.7	17
47	Prediction of Hepatocellular Carcinoma After Sustained Virological Responses Using Magnetic Resonance Elastography. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2616-2618.	2.4	17
48	Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment. <i>Liver Cancer</i> , 2016, 5, 257-268.	4.2	16
49	Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B. <i>Journal of Medical Virology</i> , 2020, 92, 1355-1358.	2.5	16
50	Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2017, 7, 244.	1.6	14
51	A Comparison of Late Mortality Among Survivors of Childhood Cancer in the United States and United Kingdom. <i>Journal of the National Cancer Institute</i> , 2021, 113, 562-571.	3.0	14
52	Impaired brain activity in cirrhotic patients with minimal hepatic encephalopathy: Evaluation by near-infrared spectroscopy. <i>Hepatology Research</i> , 2014, 44, 319-326.	1.8	12
53	Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovir. <i>JGH Open</i> , 2020, 4, 429-432.	0.7	11
54	Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2943-2951.	1.4	11

#	ARTICLE	IF	CITATIONS
55	Prognosis of intrahepatic cholangiocarcinoma stratified by albuminâ€“bilirubin grade. <i>Hepatology Research</i> , 2021, 51, 902-908.	1.8	11
56	Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease. <i>Journal of Medical Ultrasonics</i> (2001), 2021, 48, 481-487.	0.6	11
57	Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. <i>Hepatology Communications</i> , 2022, 6, 461-472.	2.0	10
58	Hepatitis B virus-related hepatocellular carcinoma in young adults: Efficacy of nationwide selective vaccination. <i>Hepatology Research</i> , 2020, 50, 182-189.	1.8	8
59	Use of the Serum Wisteria floribunda Agglutinin-Positive Mac2 Binding Protein as a Marker of Gastroesophageal Varices and Liver-Related Events in Chronic Hepatitis C Patients. <i>Diagnostics</i> , 2020, 10, 173.	1.3	8
60	Changes of liver stiffness measured by magnetic resonance elastography during direct-acting antivirals treatment in patients with chronic hepatitis C. <i>Journal of Medical Virology</i> , 2021, 93, 3744-3751.	2.5	8
61	Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup. <i>International Journal of Molecular Sciences</i> , 2021, 22, 40.	1.8	8
62	Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment. <i>Journal of Viral Hepatitis</i> , 2021, 28, 787-794.	1.0	7
63	Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment. <i>JGH Open</i> , 2022, 6, 301-308.	0.7	7
64	Impaired brain function improved by l-carnitine in patients with cirrhosis: evaluation using near-infrared spectroscopy. <i>Scientific Reports</i> , 2020, 10, 13566.	1.6	6
65	Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib. <i>JGH Open</i> , 2020, 4, 1183-1190.	0.7	6
66	Pretreatment Gastric Lavage Reduces Postoperative Bleeding after Endoscopic Submucosal Dissection for Gastric Neoplasms. <i>PLoS ONE</i> , 2016, 11, e0149235.	1.1	5
67	Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not Î±-fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3640.	1.8	5
68	Validation of albumin, bilirubin, and platelet criteria for avoiding screening endoscopy in patients with advanced fibrosis. <i>Hepatology Research</i> , 2020, 50, 996-999.	1.8	5
69	Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis. <i>JGH Open</i> , 2021, 5, 1085-1091.	0.7	5
70	Real-World Data on Ramucirumab Therapy including Patients Who Experienced Two or More Systemic Treatments: A Multicenter Study. <i>Cancers</i> , 2022, 14, 2975.	1.7	5
71	Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy. <i>Hepatology Research</i> , 2011, 41, 217-224.	1.8	4
72	Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma. <i>PLoS ONE</i> , 2022, 17, e0265235.	1.1	4

#	ARTICLE	IF	CITATIONS
73	A validation study of after direct-acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct-acting antiviral therapy and achieved sustained virological response. JGH Open, 2022, 6, 20-28.	0.7	4
74	Two cases of hepatic angiomyolipoma with different ultrasonographic and radiographic findings. Acta Hepatologica Japonica, 2008, 49, 440-448.	0.0	2
75	Significance of PIVKA-II in sorafenib therapy for advanced hepatocellular carcinoma. Acta Hepatologica Japonica, 2010, 51, 403-404.	0.0	1
76	Four cases with advanced hepatocellular carcinoma who achieved long survival, after surgical resection following to down-staging therapies. Acta Hepatologica Japonica, 2016, 57, 649-655.	0.0	1
77	Plasma Renin Activity Predicts Prognosis and Liver Disease-Related Events in Liver Cirrhosis Patients with Ascites Treated by Tolvaptan. Digestive Diseases, 2022, 40, 479-488.	0.8	1
78	Validation of magnetic resonance elastography plus FIB-4 for significant fibrosis in nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2022, , .	1.4	1
79	Two cases of acute liver failure caused by hepatitis A which were negative for serum IgM-HA antibody at the early stage of the onset. Acta Hepatologica Japonica, 2013, 54, 553-558.	0.0	0
80	Imaging Findings of Hepatocellular Carcinoma that Developed after HCV Eradication with Direct-Acting Antivirals. Acta Hepatologica Japonica, 2019, 60, 46-48.	0.0	0
81	Sorafenib therapy for advanced hepatocellular carcinoma with Vp3 or 4 portal vein tumor thrombosis. Acta Hepatologica Japonica, 2011, 52, 325-326.	0.0	0
82	<scp>General evaluation score</scp> for predicting the development of <scp>hepatocellular carcinoma</scp> in patients with advanced liver fibrosis associated with <scp>hepatitis C virus</scp> genotype 1 or 2 after <scp>direct-acting antiviral</scp> therapy. JGH Open, 2022, 6, 487-495.	0.7	0